Benzene Ring Nonionically Bonded Patents (Class 514/568)
-
Patent number: 8222267Abstract: A method of converting a treatment for pain comprising intravenous administration of opioids, to a treatment for pain comprising oral administration of a first dose of an immediate release morphine-oxycodone combination in patients in need of analgesia. The method may comprise (1) determining a four-hour average oral morphine equivalents, a one-hour average oral morphine equivalents, or determining a net average hourly intravenous dose, and (2) orally administering to the patient a first dose of a morphine-oxycodone combination in a 3:2 ratio by weight every four to six hours. Also, a method of treating pain in patients who had been administered opioids intravenously, comprising using a dosing algorithm to determine the first dose of the immediate release morphine-oxycodone combination.Type: GrantFiled: July 18, 2011Date of Patent: July 17, 2012Assignee: QRxPharma Ltd.Inventors: Patricia T. Richards, Warren C. Stern, Laurel J. Mengle-Gaw, Benjamin Schwartz
-
Publication number: 20120178732Abstract: The invention relates to substituted phenoxyacetic acids of formula (I), where the variables are as defined in claim 1, as useful pharmaceutical compounds for treating respiratory disorders, pharmaceutical compositions containing them, and processes for their preparation.Type: ApplicationFiled: December 6, 2011Publication date: July 12, 2012Inventors: Timothy Jon Luker, Timothy Nicholas Birkinshaw, Rukhsana Tasneem Mohammed
-
Publication number: 20120178697Abstract: The Wnt signaling pathways are involved in embryo development as well as in tumorigenesis. Dishevelled (Dvl) tranduces Wnt signals from the receptor Frizzled (Fz) to downstream components in canonical and non-canonical Wnt signaling pathways, and the Dvl PDZ domain plays an essential role in both pathways, and the Dvl PDZ domain binds directly to Fz receptors. In the present invention using NMR-assisted virtual ligand screening, several compounds were identified and were found to bind to the Dvl PDZ domain. Molecular dynamics simulation was used to analyze the binding between the PDZ domain and these compounds in detail. These compounds provide a basis for rational design of high-affinity inhibitors of the PDZ domain, which can block Wnt signaling by interrupting the Fz-Dvl interaction.Type: ApplicationFiled: April 1, 2005Publication date: July 12, 2012Inventors: Jie Zheng, Jufang Shan, Dianqing Wu
-
Patent number: 8217078Abstract: The field involves compositions useful for pain relief, including diclofenac solution and gel formulations, in particular methods of use thereof, articles of manufacture and kits that provide novel preclinical, clinical and other information to users.Type: GrantFiled: October 28, 2010Date of Patent: July 10, 2012Assignee: Nuvo Research Inc.Inventors: Jagat Singh, Joseph Zev Shainhouse, Bradley S. Galer, Robert Dominic King-Smith, Lisa Marie Grierson, Maria Burian, Jonathan Wilkin, Edward T. Kisak, John M. Newsam
-
Patent number: 8198329Abstract: A medicament for promoting memory consolidation, which comprises, as an active ingredient, a non-natural retinoid, preferably a retinoid having a basic skeleton comprising an aromatic ring bound with an aromatic carboxylic acid or tropolone by means of a bridging group, more preferably 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)carbamoyl]benzoic acid or 4-[(3,5-bis-trimethylsilylphenyl)-carboxamido]benzoic acid.Type: GrantFiled: March 9, 2005Date of Patent: June 12, 2012Assignees: Research Foundation Itsuu Laboratory, Kemphys Ltd.Inventors: Koichi Shudo, Hiroyuki Kagechika
-
Patent number: 8188296Abstract: The present invention relates to stabilized 123I-labelled radiopharmaceutical compositions having a stabilizer which comprises gentisic acid or a salt thereof with a biocompatible cation. Methods of preparation of the stabilized radioiodine compositions as well as the use of gentisic acid to stabilize 123I-labelled radiopharmaceutical at a specified radioactive concentration range are also described.Type: GrantFiled: March 31, 2006Date of Patent: May 29, 2012Assignee: GE Healthcare LimitedInventors: Ton Janssen, Jan Van Den Bos
-
Publication number: 20120122910Abstract: Disclosed herein are methods of treating cancer by administering to a patient a small molecule inhibitor of Survivin. Also disclosed herein are methods of inhibiting Survivin dimerization in a patient by administering a compound of formula (I), (II), (III), or (IV). Methods of inducing cell cycle arrest in cancer cells, comprising G2/M stage arrest, in a patient by administering a compound of formula (I), (II), (III), or (IV) are also disclosed. Further disclosed herein are methods of inducing apoptosis in cancer cells in a patient by administering a compound of formula (I), (II), (III), or (IV).Type: ApplicationFiled: January 19, 2010Publication date: May 17, 2012Applicant: The Trustees Of The University Of PennsylvaniaInventors: Alan Berezov, Qiang Wang, Ramachandran Murali, Mark I. Greene
-
Publication number: 20120114637Abstract: Diseases and conditions associated with tissues of the body, including but not limited to tissues in the eye, can be effectively treated, prevented, inhibited, onset delayed, or regression caused by administering therapeutic agents to those tissues. Described herein are ophthalmic formulations that deliver a variety of therapeutic agents, including but not limited to rapamycin (sirolimus), analogs thereof (rapalogs) or other mTOR inhibitors, to a subject for an extended period of time. The ophthalmic formulations may be placed in an aqueous medium of a subject, including but not limited to intraocular or periocular administration, or placement proximate to a site of a disease or condition to be treated in a subject. A method may be used to administer a therapeutic agent to treat or prevent age-related macular degeneration, macular edema, diabetic retinopathy, uveitis, dry eye, or a hyperpermeability disease in a subject.Type: ApplicationFiled: May 4, 2010Publication date: May 10, 2012Applicant: SANTEN PHARMACEUTICAL CO., LTD.Inventors: Thierry Nivaggioli, David A. Weber, Philippe JM Dor, Philip Reilly
-
Publication number: 20120115912Abstract: A method of treating a PPAR? and/or RXR related disease or disorder in a subject includes adminstering to the subject an RXR agonist alone or in combination with a PPAR? agonist.Type: ApplicationFiled: July 12, 2010Publication date: May 10, 2012Inventors: Gary E. Landreth, Paige E. Cramer
-
Patent number: 8173704Abstract: The present application relates to novel difluorophenol derivatives, processes for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for producing medicaments for the treatment and/or prophylaxis of diseases, especially for the treatment and/or prevention of cardiovascular disorders.Type: GrantFiled: October 9, 2006Date of Patent: May 8, 2012Assignee: Bayer Pharma AktiengesellschaftInventors: Stephan Bartel, Michael Hahn, Wahed Ahmed Moradi, Eva-Maria Becker, Thomas Rölle, Johannes-Peter Stasch, Karl-Heinz Schlemmer, Frank Wunder, Andreas Knorr
-
Publication number: 20120107414Abstract: The present invention relates to pharmaceutical formulations for treating a respiratory tract infection or a pulmonary disease in an individual, comprising a calcium salt and a sodium salt, wherein the ratio of Ca+2 to Na+ is from about 4:1 (mole:mole) to about 16:1 (mole:mole). The invention also relates to methods of treating (including prophylactically treating) and reducing the spread of a respiratory tract infection, methods of treating (including prophylactically treating) a pulmonary disease or an acute exacerbation of a pulmonary disease, and methods of reducing the spread of an acute exacerbation of a pulmonary disease, comprising administering a pharmaceutical formulation that comprises a calcium salt and a sodium salt.Type: ApplicationFiled: March 26, 2010Publication date: May 3, 2012Applicant: Pulmatrix, Inc.Inventors: Michael M. Lipp, Robert W. Clarke, David L. Hava, Richard Batycky, John Hanrahan
-
Publication number: 20120108551Abstract: The present invention relates to compositions that may alleviate symptoms of ocular stress, as well as methods of their production, use, and storage compositions. The compositions comprise at least one ocular epithelial cell associating group and at least one hydrophilic group. In one embodiment the at least one ocular epithelial cell associating group and at least one hydrophilic group are substituents on a conjugated polyaromatic core. The compositions may be used in ophthalmic compositions and ophthalmic devices.Type: ApplicationFiled: October 29, 2010Publication date: May 3, 2012Inventors: Frank F. Molock, JR., John C. Heaton
-
Patent number: 8168649Abstract: The present invention encompasses compounds of Formula (I): as well as pharmaceutically acceptable salts and hydrates thereof, that are useful for treating atherosclerosis, dyslipidemias and the like. Pharmaceutical compositions and methods of use are also included.Type: GrantFiled: June 26, 2006Date of Patent: May 1, 2012Assignee: Merk Sharp & Dohme Corp.Inventors: Subharekha Raghavan, Steven L. Colletti, Fa-Xiang Ding, Hong Shen, James R. Tata, Ashley Rouse Lins, Abigail Lee Smenton, Weichun Chen, Darby Rye Schmidt, George Scott Tria
-
Publication number: 20120101067Abstract: Described herein are methods for improving engraftment of hematopoietic cells in an individual following hematopoietic progenitor cell transplantation (e.g., via bone marrow or cord blood transplantation). Methods for increasing hematopoietic progenitor cell proliferation in individuals with bone marrow aplasia are also described. The methods involve administering an agent that inhibits adipogenesis, adipocyte growth, adipocyte differentiation and/or adipocyte proliferation.Type: ApplicationFiled: April 15, 2010Publication date: April 26, 2012Applicant: CHILDREN'S MEDICAL CENTER CORPORATIONInventors: Olaia Naveiras, George Daley, Pamela L. Wenzel
-
Publication number: 20120100084Abstract: Water-soluble or water-swellable polymers are described, containing a) 20.0 to 98.99 mole percent of one or more independently recurring structural units of the formula (1) and b) 1.0 to 79.99 mole percent of one or more independently recurring structural units of the formula (2), and c) 0.01 to 8.0 mole percent of one or more independently recurring cross-linking structural units, which are obtained from one or more monomers having at least two olefinic double bonds. The polymers are suitable, for example, as thickeners or yield point formers, in particular in cosmetic, dermatological or pharmaceutical compositions.Type: ApplicationFiled: March 20, 2010Publication date: April 26, 2012Applicant: CLARIANT FINANCE (BVI) LIMITEDInventors: Klug Peter, Dirk Fischer, Thomas Lindner, Matthias Kunze, Wiebke Moeller, Carina Mildner, Sebastiano Lo Vasco
-
Patent number: 8158681Abstract: The present invention relates to new methoxylated aromatic compounds. It also relates to novel compositions comprising methoxylated aromatic compounds as well as to the use of these compositions as a medicament, in particular as a medicament for the treatment, co-treatment or prevention of inflammatory disorders.Type: GrantFiled: February 13, 2007Date of Patent: April 17, 2012Assignee: DSM IP Assets B.V.Inventors: Daniel Raederstorff, Joseph Schwager, Goede Schueler
-
Publication number: 20120088671Abstract: The present invention provides polyphenolic compositions derived from a plant that inhibit the formation of a biofilm. Also provided are combinations that comprise at least one phenolic phytochemical and at least one antimicrobial agent that inhibit the growth of an established biofilm. Further, the present invention provides methods for inhibiting the formation and growth of biofilms.Type: ApplicationFiled: October 6, 2011Publication date: April 12, 2012Applicant: BOARD OF TRUSTEES UNIVERSITY OF ARKANSASInventors: Cassandra L. Quave, Mark S. Smeltzer, Cesar M. Compadre, Howard Hendrickson
-
Publication number: 20120082722Abstract: Disclosed are oral dosage forms containing a Ras antagonist including FTS and structural analogs thereof, and at least one pharmaceutically acceptable excipient other than a cyclodextrin, and methods of orally administering same to treat diseases and disorders responsive to the Ras antagonists.Type: ApplicationFiled: December 15, 2011Publication date: April 5, 2012Applicant: CONCORDIA PHARMACEUTICALS, INC.Inventor: Victor J. Bauer
-
Patent number: 8148416Abstract: A pharmaceutical composition and a method of treating inflammation in a mammal. The method administers the therapeutic composition to the mammal. The therapeutic composition includes: a standard therapeutic dose of a COX2 inhibitor consisting of celecoxib or rofecoxib; and low dose aspirin in an amount of 70-85 mg.Type: GrantFiled: January 21, 2008Date of Patent: April 3, 2012Inventors: Mawaheb M. El-Naggar, Ahmed S. Mousa
-
Patent number: 8143309Abstract: A composition and method are described for sanitizing or otherwise treating a material such as a non-living surface, living tissue, soil or atmosphere which may be contaminated by a toxin, chemical warfare agent, insect, prion, microorganism or other infectious agent. The composition generally includes an aqueous composition mixture that includes: (a) lower alkanol; (b) an alkalinating agent, and (c) a fatty acid salt and/or ester. The components are present in an effective amount to sanitize (or treat) a material (or modifying a chemical contained thereon) to which the composition is applied. Also described are methods of making the composition.Type: GrantFiled: April 28, 2009Date of Patent: March 27, 2012Assignee: UrthTech, LLCInventor: Aziz C. Awad
-
Publication number: 20120071550Abstract: The present invention provides a therapeutic composition comprising one or more polyphenols and one or more carotenoids selected from the group consisting of lutein, lycopene and beta-carotene. The invention also provides methods for inhibiting or reducing the production of superoxide ions, NO, TNF-alpha and/or PGE2 in a mammalian subject comprising administering to said subject the aforementioned therapeutic composition.Type: ApplicationFiled: July 18, 2011Publication date: March 22, 2012Applicant: LYCORED LTD.Inventors: Morris Zelkha, Rachel Levy, Esther Paran, Yoav Sharoni, Joseph Levy
-
Publication number: 20120059062Abstract: Cannabinoids, in particular CBD and CBDA and their acid derivatives are provided for use as an active pharmaceutical substance in the treatment of nausea, vomiting, emesis, motion sickness. In particular extracts of cannabis plants are presented which are rich in these substances and suitable for pharmaceutical use.Type: ApplicationFiled: August 31, 2011Publication date: March 8, 2012Applicant: GW Pharma LimitedInventors: Brian Whittle, Farideh Afshin Javid
-
Publication number: 20120052118Abstract: The present invention provides an apparatus and process for making softgel capsules having incorporated therein other solid dosage forms selected from the group consisting of pellets, smaller capsules, smaller tablets, sustained release solid dosage forms, immediate release solid dosage forms, extended release solid dosage forms and zero order release solid dosage forms, said apparatus comprising: (a) two spreader boxes; (b) two casting drums; (c) a pair of rotary dies having means for suction; (d) a liquid fill system; (e) a wedge for heating gelatine ribbons and feeding said fill; and (f) two lateral dispensing devices said lateral dispensing devices including hoppers having said solid dosage forms, channelguides for transporting said solid dosage forms and a grasping claw for dispensing said solid dosage form into the softgel pocket formed in the rotary dies.Type: ApplicationFiled: July 18, 2011Publication date: March 1, 2012Inventors: Carlos Salazar Altamar, Gustavo Anaya, Braulio Teran, Newman Aguas Navarro, Willmer Herrera
-
Publication number: 20120053133Abstract: A novel antiseptic agent composition which has a wide antimicrobial spectrum and excellent antiseptic properties is provided. An antiseptic agent composition A contains a glycerin hydroxy fatty acid monoester that is an ester of glycerin and a hydroxy fatty acid having 8 to 18 carbon atoms, and a specific antiseptic agent such as an alkanediol. An antiseptic agent composition B contains the glycerin hydroxy fatty acid monoester and an aromatic antiseptic agent. An antiseptic agent composition C contains the glycerin hydroxy fatty acid monoester and a chelating agent.Type: ApplicationFiled: January 18, 2010Publication date: March 1, 2012Applicant: TAIYO CORPORATIONInventors: Shuji Kanatani, Soota Iwamoto
-
Publication number: 20120035139Abstract: Gamma-amino-butyric acid derivatives that are GABAB receptor ligands, pharmaceutical compositions comprising such derivatives, and methods of using such derivatives and pharmaceutical compositions thereof for treating diseases are disclosed.Type: ApplicationFiled: April 16, 2010Publication date: February 9, 2012Inventors: Feng Xu, Mark A. Gallop, Ge Peng, Thu Phan, Usha Dilip, David J. Wustrow
-
Publication number: 20120027833Abstract: Polymeric porous films, capable of eluding a bioactive agent when coming in contact with a physiological medium according to a pre-determined and controlled release profile suitable for particular type of drug and indication, and medical devices including the same are disclosed. Also disclosed are processes for producing the polymeric porous films by freeze-drying an inverted emulsion formulation in which the polymer's composition, the polymer's concentration, the polymer's initial molecular weight, the concentration and/or the type of a surfactant, the homogenization rate and/or the oil phase to aqueous phase ratio (O:A) are selected so as to impart a desired release profile of the bioactive agent from the polymeric film.Type: ApplicationFiled: August 2, 2011Publication date: February 2, 2012Applicant: Ramot at Tel-Aviv University Ltd.Inventor: Meital ZILBERMAN
-
Patent number: 8106236Abstract: The present invention relates to compounds having the general formula (I) with the definitions of X, Y, R1, R2, R3, R4, R9, R10 given below, and solvates, hydrates, esters, and pharmaceutically acceptable salts thereof. Furthermore the invention relates to the use of said compounds for the treatment of Alzheimer's disease and their use for the modulation of ?-secretase activity.Type: GrantFiled: April 19, 2007Date of Patent: January 31, 2012Assignee: Ortho-McNeil Pharmaceutical, Inc.Inventors: Francis Wilson, Alison Reid, Valerie Reader, Richard John Harrison, Mihiro Sunose, Remedios Hernandez-Perni, Jeremy Major, Cyrille Boussard, Kathryn Smelt, Jess Taylor, Adeline LeFormal, Andrew Cansfield, Svenja Burckhardt, Yan Zhang, Chih Yung Ho
-
Publication number: 20120015912Abstract: The present invention relates to the use of a compound of Formula (IIV) or pharmaceutically acceptable salt or solvate, isomer or prodrug thereof in the manufacturing of a medicament for the treatment and/or prophylaxis of any of the diseases selected from the group consisting of macular degeneration, corneal neovascularization or angiogenesis, iris neovascularization or angiogenesis, retinal neovascularization or angiogenesis, diabetic proliferative retinopathy and non-diabetic proliferative retinopathy.Type: ApplicationFiled: January 7, 2011Publication date: January 19, 2012Applicant: Action MedicinesInventors: Pedro Cuevas SĂ¡nchez, Guillermo Gimenez Gallego, Inigo Saenz de Tejada Morgan, Maria Luisa Krauel, Javier Angulo Frutos, Rosa Maria Lozano Puerto, Antonio Romero Garrido, Serafin Valverde Lopez
-
Publication number: 20120015422Abstract: The present disclosure relates to fermentation broth formulations containing organic acids and/or organic acid salts, and methods of making and using such formulations.Type: ApplicationFiled: February 19, 2010Publication date: January 19, 2012Inventors: Tom Tao Huang, Aaron Kelley, John Mclaughlin
-
Patent number: 8097652Abstract: The present invention relates to a compound of Formula (I) or a pharmaceutically acceptable salt thereof which is useful for the treatment of conditions associated with glutamate hypofunction, such as psychiatric and neurological disorders.Type: GrantFiled: December 6, 2007Date of Patent: January 17, 2012Assignee: Eli Lilly and CompanyInventor: Esteban Dominguez-Manzanares
-
Patent number: 8071641Abstract: Use of a cannabidiol for the manufacture of a medicament identified for the treatment or prevention of diabetes and/or insulitis.Type: GrantFiled: February 16, 2005Date of Patent: December 6, 2011Assignees: Yissum Research Development Company of the Hebrew University of Jerusalem, Hadsit Hadasit Medical Research Services and Development Ltd.Inventors: Lola Weiss, Michael Zeira, Raphael Mechoulam, Shimon Slavin, Ruth Gallily
-
Publication number: 20110293582Abstract: Described herein are methods for enhancing engraftment of hematopoietic stem and progenitor cells using farnesyl compounds identified using a zebrafish model of hematopoietic cell engraftment. The compounds can be used to treat hematopoietic stem cells ex vivo prior to transplantation of the cells. Alternatively, the compounds can be administered to an individual undergoing cell transplantation.Type: ApplicationFiled: February 3, 2010Publication date: December 1, 2011Applicant: CHILDREN'S MEDICAL CENTER CORPORATIONInventors: Leonard I. Zon, Pulin Li
-
Publication number: 20110288161Abstract: Certain embodiments in the present invention provide for methods for therapy of lung diseases and other conditions such as infection are provided. In certain embodiments, the methods comprise one or more agents capable of increasing thiol-containing compound transport via a transporter system (i.e., ABC transporters such as MDR-1 or MRP-2) in cells. Other embodiments can include the use of agents to modulate transport of thiol-containing compounds from the cell such as thiocyanate. In certain embodiments, therapeutic methods involve the administration of such agents to a patient afflicted with an inflammatory condition or infection responsive to stimulation of thiol-containing compound transport.Type: ApplicationFiled: March 15, 2011Publication date: November 24, 2011Inventor: Brian J. Day
-
Publication number: 20110275581Abstract: A method of treating cancer in a subject comprising the step of administering to the subject in need thereof an effective amount of a combination of a compound that binds a nuclear export signal (NES inhibitor) on topoisomerase II? and a topoisomerase inhibitor. Twenty small molecule inhibitors (SMI) that bind to the two nuclear export sequences (NES) topo II? have been identified from the NCI database using computer-generated molecular modeling. These SMI will improve the effectiveness of topo II directed therapeutics, particularly in the treatment of diseases such as multiple myeloma (MM). In vitro apoptosis assays indicate that these drugs may be effective as single agents or in combination with currently used cancer drugs that target topo II.Type: ApplicationFiled: June 13, 2011Publication date: November 10, 2011Applicants: University of Florida Research Foundation, Inc., H. Lee Moffitt Cancer Center and Research Institute, Inc.Inventors: Daniel M. Sullivan, Joel G. Turner, Thomas C. Rowe, David A. Ostrov
-
Patent number: 8053475Abstract: A pharmaceutical composition comprising at least 0.1 ?mol of formaurindicarboxylic acid or its derivatives in 1 kg of pharmaceutically acceptable carrier. The pharmaceutical composition of claim 1 wherein the composition is in the form of solution prepared using aqueous alcali or water.Type: GrantFiled: September 10, 2010Date of Patent: November 8, 2011Assignee: Vyzkumny Ustav Zivocisne Vyroby, V.V.I.Inventor: Pavel Klein
-
Publication number: 20110268659Abstract: In this disclosure, methods and systems for drug delivery utilizing high shear are disclosed. In an embodiment, a method comprises (1) subjecting a therapeutic fluid containing a drug to high shear; and (2) obtaining a processed therapeutic fluid, wherein the processed therapeutic fluid contains the drug in nano-size. In an embodiment, a method comprises (1) subjecting a drug carrier and a therapeutic fluid containing a drug to high shear; and (2) obtaining a processed therapeutic fluid, wherein the processed therapeutic fluid contains the drug carrier loaded with the drug. In an embodiment, a method comprises (1) applying high shear to a drug carrier and a therapeutic fluid containing a drug; (2) obtaining a processed therapeutic fluid, wherein the processed therapeutic fluid contains the drug-loaded carrier; and (3) modifying the drug-loaded carrier with a targeting moiety to obtain a modified drug-loaded carrier.Type: ApplicationFiled: April 8, 2011Publication date: November 3, 2011Applicant: H R D CorporationInventors: Abbas HASSAN, Rayford G. ANTHONY, Aziz HASSAN
-
Publication number: 20110263692Abstract: A compound having a structure is disclosed herein. Compositions, medicaments, and therapeutic methods related thereto are also disclosed.Type: ApplicationFiled: July 5, 2011Publication date: October 27, 2011Applicant: ALLERGAN, INC.Inventors: Donde Yariv, Jeremiah H. Nguyen
-
Patent number: 8044059Abstract: The use of an N,N-dimethyl alkylamide or an N-alkanoyl morpholine provides a stable emulsifiable concentrate composition that hinders de-esterification and transesterification of mixtures of a carboxylic acid herbicide and an ester of a different carboxylic acid herbicide. The N,N-dimethyl alkylamide or N-alkanoyl morpholine additionally stabilizes emulsifiable concentrates containing a triazolopyrimidine herbicide having at least one methoxy group on the triazolopyrimidine ring.Type: GrantFiled: February 20, 2009Date of Patent: October 25, 2011Assignee: Dow AgroSciences LLCInventors: Derek J. Hopkins, Robert Matthew Buttimor
-
Publication number: 20110257258Abstract: A method and composition for preventing and treating Avian Influenza in Humans utilizes an effective quantity of polyphenolic(s) and/or its derivatives in combination with a carrier. The anti-avian influenza ingredient having a composition selected from the group consisting of theaflavin, theaflavin-3,3?-digallate, theaflavin-3-monogallate, theaflavin-3 gallate, theaflavin-3?-gallate, thearubigin, gallic acid, tannic acid, (?)-epigallocatechin gallate (EGCG), (?) epigallocatechin (EGC), (+)-epicatechin (EC), (?)-gallocatechin gallate (GCG), and catechin.Type: ApplicationFiled: June 23, 2011Publication date: October 20, 2011Inventors: Charles Hensley, Sung Pyo
-
Publication number: 20110257264Abstract: The present invention relates to the use of a 2,5-dihydroxybenzene derivative represented by Formula (I) or a pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the therapeutic and/or prophylactic treatment of, inter alia, actinic keratosis.Type: ApplicationFiled: November 15, 2010Publication date: October 20, 2011Applicant: Action MedicinesInventors: Pedro Cuevas S?nchez, Guillermo Gimenez Gallego, Inigo Saenz de Tejada Morgan, Javier Angulo Frutos, Serafin Valverde Lopez, Antonio Romero Garrido, Rosa Maria Lozano Puerto
-
Patent number: 8039484Abstract: Diaryl ethers in which one of the aryl groups is a phenyl fused to a cycloalkyl or heterocyclic ring, to which is attached an acetic acid group, are agonists of G-protein coupled receptor 40 (GPR40) and are useful as therapeutic compounds, particularly in the treatment of Type 2 diabetes mellitus, and of conditions that often accompany this disease, including insulin resistance, obesity and lipid disorders.Type: GrantFiled: October 26, 2007Date of Patent: October 18, 2011Assignee: Merck Sharp & Dohme Corp.Inventors: Min Ge, Songnian Lin, Shawn P. Walsh, Lihu Yang, Changyou Zhou
-
Publication number: 20110251146Abstract: A topical, foamable composition is provided that includes at least one antifungal agent that is able to penetrate the upper layers of skin and is retained in or on an area to be treated for a prolonged period of time, and that has a residual non-volatile component content less than 25%. In addition, a method of treating fungal diseases including jock itch, tinea, dandruff and sebborheic dermatitis is provided, and includes applying to the affected area of patient requiring such treatment an antifungal composition.Type: ApplicationFiled: June 21, 2011Publication date: October 13, 2011Applicant: STIEFEL RESEARCH AUSTRALIA PTY LTDInventors: Greg DAVEY, Albert Zorko ABRAM
-
Patent number: 8034843Abstract: Cannabinoids, in particular CBD and CBDA and their acid derivatives are provided for use as an active pharmaceutical substance in the treatment of nausea, vomiting, emesis, motion sickness. In particular extracts of cannabis plants are presented which are rich in these substances and suitable for pharmaceutical use.Type: GrantFiled: February 3, 2003Date of Patent: October 11, 2011Assignee: GW Pharma LimitedInventors: Brian Whittle, Farideh Afshin Javid
-
Publication number: 20110243911Abstract: The present invention is directed to the use of a compound capable of reducing the uric acid level in a mammal for the prevention and/or the treatment of IL-1? driven lung pathology, particularly to treat lung inflammation such as chronic fibrosis, COPD and interstitial fibrosis and other IL-1? driven lung pathologies including those of autoimmune origin. Preferred compounds capable of reducing the uric acid level are selected from the group consisting of xanthine oxidase inhibitors, such as allopurinol, recombinant enzyme uricase and uricosuric compound capable of enhancing uric acid excretion, such as probenecid. The invention further relates to a method for identifying in vitro whether a patient presents an IL-1? driven lung pathology or is at risk to develop an IL-1? driven lung pathology, or for the screening of a compound for treating an IL-1? driven lung pathology.Type: ApplicationFiled: September 18, 2009Publication date: October 6, 2011Inventors: Bernhard Ryffel, Isabelle Couillin
-
Patent number: 8030353Abstract: A pharmaceutical composition comprising at least 0.1 ?mol of formaurindicarboxylic acid or its derivatives in 1 kg of pharmaceutically acceptable carrier. The pharmaceutical composition of claim 1 wherein the composition is in the form of solution prepared using aqueous alcali or water.Type: GrantFiled: April 16, 2008Date of Patent: October 4, 2011Assignee: Vyzkumny Ustav Zivocisne Vyroby, V.V.I.Inventor: Ing. Pavel Klein
-
Publication number: 20110230560Abstract: The present invention relates to a composition comprising a synergetic mixture of flavourings or flavouring substances and organic acids. Moreover, the present invention relates to the use of said composition as a preservative for animal foodstuffs and additives intended preferably for monogastric animals.Type: ApplicationFiled: August 4, 2008Publication date: September 22, 2011Applicant: VETAGRO S.P.A.Inventors: Andrea Piva, Maurizio Tedeschi
-
Publication number: 20110224300Abstract: The present invention discloses the use of potassium 2-(?-hydroxypentyl) benzoate in the manufacture of medicaments for preventing, relieving or treating senile dementia diseases or symptom, and for relieving oxidative stress injury in brain tissue, increasing neural function of choline, protecting neuron and/or raising the content of brain nerve growth factor. The present invention also discloses a pharmaceutical composition comprising potassium 2-(?-hydroxypentyl) benzoate in prophylactically or therapeutically effective dose, optionally, a pharmaceutically acceptable carrier and/or adjuvant.Type: ApplicationFiled: July 8, 2008Publication date: September 15, 2011Applicant: Institute of Mataria Medica, Chinese Academy of MeInventors: Xiaoliang Wang, Wanhong Zhao, Jinghua Yang, Ling Wang, Jiang Li, Shaofeng Xu, Nan Feng, Shiping Ma
-
Publication number: 20110218226Abstract: A method of reducing the virulence of a bacterium that expresses accessory gene regulator A (AgrA) includes administering to the bacterium an amount of AgrA antagonist effective to inhibit the synthesis of one or more virulence factors by the bacterium.Type: ApplicationFiled: March 8, 2011Publication date: September 8, 2011Inventor: MENACHEM SHOHAM
-
Publication number: 20110218248Abstract: The present invention relates to salts, polymorphs and hydrates of 2-Amino-2-[2-(4-C2-20-alkyl-phenyl)ethyl]propane-1,3-diol, and to the use thereof, in particular in the treatment or prevention of various autoimmune conditions.Type: ApplicationFiled: November 10, 2009Publication date: September 8, 2011Inventors: Guido Jordine, Michael Mutz
-
Patent number: 8012990Abstract: A method of converting a treatment for pain comprising intravenous administration of opioids, to a treatment for pain comprising oral administration of a first dose of an immediate release morphine-oxycodone combination in patients in need of analgesia. The method may comprise (1) determining a four-hour average oral morphine equivalents or determining a net average hourly intravenous dose, and (2) orally administering to the patient a first dose of a morphine-oxycodone combination in a 3:2 ratio by weight every four to six hours. Also, a method of treating pain in patients who had been administered opioids intravenously, comprising using a dosing algorithm to determine the first dose of the immediate release morphine-oxycodone combination.Type: GrantFiled: September 14, 2010Date of Patent: September 6, 2011Assignee: QRxPharma Ltd.Inventors: Patricia T. Richards, Warren C. Stern, Laurel J. Mengle-Gaw, Benjamin D. Schwartz